Understanding Heberprot-P: A Breakthrough in Diabetic Foot Ulcer Treatment

Heberprot-P is a unique Cuban biotechnology product: a recombinant human Epidermal Growth Factor (hEGF) administered by intralesional injection for the treatment of complex diabetic foot ulcers. Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, it offers a treatment option for wounds that have not responded to conventional therapy.

The clinical challenge is significant: diabetic foot ulcers are among the most serious complications of diabetes and frequently lead to amputation when standard treatments fail. Heberprot-P is injected directly into the wound edges, typically three times per week for up to eight weeks, stimulating cellular proliferation and tissue regeneration at the wound site. It is combined with standard wound care.

Heberprot-P is registered in over 26 countries and has been used to treat thousands of patients. Clinical studies have demonstrated significant healing rates in ulcers that had not responded to conventional treatment, with a marked reduction in amputation risk. Individual results vary based on wound characteristics and patient health status.